Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services.
Company profile
Ticker
HAE
Exchange
Website
CEO
Christopher Simon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
5D Information Management, Inc. • Arryx, Inc. • Cardiva Medical, Inc. • Enicor GmbH • Global Med Technologies, Inc. • Haemonetics (Hong Kong) Limited • Haemonetics (UK) Limited • Haemonetics Asia Incorporated • Haemonetics Asia UK Ltd. • Haemonetics Australia PTY Ltd. ...
IRS number
42882273
HAE stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
7 Feb 23
8-K
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2023 Results; Updates Fiscal 2023 Guidance
7 Feb 23
10-Q
2023 Q2
Quarterly report
8 Nov 22
8-K
Haemonetics Reports Second Quarter and First Half Fiscal 2023 Results; Updates Fiscal 2023 Guidance
7 Nov 22
8-K
Departure of Directors or Certain Officers
19 Oct 22
10-Q
2023 Q1
Quarterly report
10 Aug 22
8-K
Haemonetics Reports First Quarter Fiscal 2023 Results; Updates Fiscal 2023 Guidance; Announces New $300 Million Share Repurchase Authorization
10 Aug 22
8-K
Departure of Directors or Certain Officers
8 Aug 22
8-K
Entry into a Material Definitive Agreement
1 Aug 22
DEFA14A
Additional proxy soliciting materials
17 Jun 22
Transcripts
HAE
Earnings call transcript
2023 Q2
7 Nov 22
HAE
Earnings call transcript
2023 Q1
10 Aug 22
HAE
Earnings call transcript
2022 Q4
10 May 22
HAE
Earnings call transcript
2022 Q3
8 Feb 22
HAE
Earnings call transcript
2022 Q2
9 Nov 21
HAE
Earnings call transcript
2022 Q1
11 Aug 21
HAE
Earnings call transcript
2021 Q4
13 May 21
HAE
Earnings call transcript
2021 Q3
2 Feb 21
HAE
Earnings call transcript
2021 Q2
4 Nov 20
HAE
Earnings call transcript
2020 Q1
9 Aug 20
Latest ownership filings
SC 13G/A
Capital Research Global Investors
13 Feb 23
SC 13G/A
Neuberger Berman Group LLC
10 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 23
SC 13G/A
BlackRock Inc.
26 Jan 23
4
Josep Llorens
25 Jan 23
SC 13G/A
BlackRock Inc.
20 Jan 23
4
Christopher Simon,
15 Nov 22
4
Roy Galvin
3 Nov 22
4
Stewart W Strong
26 Oct 22
Financial summary
| Quarter (USD) | Dec 22 | Oct 22 | Jul 22 | Apr 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Apr 22 | Apr 21 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 224.00 mm | 224.00 mm | 224.00 mm | 224.00 mm | 224.00 mm | 224.00 mm |
| Cash burn (monthly) | 5.73 mm | 1.07 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 17.30 mm | 3.24 mm | n/a | n/a | n/a | n/a |
| Cash remaining | 206.70 mm | 220.76 mm | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 36.1 | 205.8 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2022
99.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 293 |
| Opened positions | 52 |
| Closed positions | 24 |
| Increased positions | 101 |
| Reduced positions | 102 |
| 13F shares | Current |
|---|---|
| Total value | 3.82 tn |
| Total shares | 50.36 mm |
| Total puts | 95.10 k |
| Total calls | 31.70 k |
| Total put/call ratio | 3.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Capital Research Global Investors | 5.96 mm | $468.44 bn |
| BLK Blackrock | 5.87 mm | $461.99 bn |
| Vanguard | 5.24 mm | $412.35 bn |
| Wellington Management | 4.03 mm | $317.33 bn |
| Neuberger Berman | 3.87 mm | $304.66 bn |
| STT State Street | 1.69 mm | $133.06 bn |
| BEN Franklin Resources | 1.35 mm | $106.31 bn |
| FMR | 1.23 mm | $97.02 bn |
| Fisher Asset Management | 1.11 mm | $87.04 mm |
| Schroder Investment Management | 952.98 k | $74.95 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 23 Jan 23 | Llorens Josep | Common Stock | Sell | Dispose S | No | Yes | 90 | 2,391 | 215.19 k | 17,234 |
| 23 Jan 23 | Llorens Josep | Common Stock | Option exercise | Acquire M | No | Yes | 56.57 | 2,391 | 135.26 k | 19,625 |
| 23 Jan 23 | Llorens Josep | NQSO Common Stock | Option exercise | Dispose M | No | Yes | 56.57 | 2,391 | 135.26 k | 7,173 |
| 11 Nov 22 | Simon, Christopher | Common Stock | Gift | Dispose G | No | No | 0 | 8,600 | 0.00 | 205,124 |
| 1 Nov 22 | Roy Galvin | Common Stock | Grant | Acquire A | No | No | 0 | 2,382 | 0.00 | 2,382 |
| 1 Nov 22 | Roy Galvin | NQSO Common Stock | Grant | Acquire A | No | No | 83.96 | 5,263 | 441.88 k | 5,263 |
| 24 Oct 22 | Basil Michelle L | Common Stock | Sell | Dispose S | No | No | 80.39 | 180 | 14.47 k | 32,455 |
| 24 Oct 22 | Stewart W Strong | Common Stock | Sell | Dispose S | No | No | 80.39 | 75 | 6.03 k | 15,681 |
News
Morgan Stanley Maintains Equal-Weight on Haemonetics, Raises Price Target to $88
8 Feb 23
Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $95
8 Feb 23
Looking Into Haemonetics's Return On Capital Employed
8 Feb 23
Alphabet To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Wednesday
8 Feb 23
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $103
8 Feb 23
Press releases
Vivasure Medical Announces FDA IDE Approval to Initiate U.S. Pivotal Study
13 Mar 23
Haemonetics Introduces Next Generation "Intelligent Control" Software for Cell Saver® Elite®+ Autotransfusion System
2 Mar 23
Haemonetics to Present at Raymond James 44th Annual Institutional Investors Conference
27 Feb 23
Haemonetics 3rd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
7 Feb 23
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2023 Results: February 7, 2023
6 Jan 23